Agoracom Blog

CLIENT FEATURE: CardioComm Solutions $ – Connecting Your Heart To The Cloud $ $ $ $ $

Posted by AGORACOM-JC at 5:37 PM on Monday, September 16th, 2019

Global Leaders in Mobile ECG Connectivity

  • 20 years of medical credibility licensing technologies to hospitals, physicians, remote patient monitoring  platforms, research groups and commercial call centers
  • Sold into > 20 countries, with the largest customer base located in the US
  • Class II medical device clearances and device agnostic for collecting, viewing, recording, analyzing and  storing of ECGs for management of patient and consumer health
  • ECG solutions for both consumer (OTC) and medical (Rx) markets
  • Owns all IP and source code
  • Market expert contributor for reports in m‐health, mobile cardiac monitoring and new advances in  consumer health and wellness monitoring

Recent Highlights

  • Announced ECG Services Integration and Co-Marketing Agreement with California-Based BodiMetrics LLC Read More
    • GEMS™ Universal will be available under two subscription models:
    • $6 US per month with one free ECG interpretation included; and,
    • $69 US per year with 12 free ECG interpretations that may be requested any time during the one year subscription.
  • GEMS(TM) Universal ECG App Launched in Partnership with Multiple ECG Device Manufacturers Read More
    • GEMS™ Universal ECG app , a version of the Company’s US Food and Drug Administration cleared and Health Canada approved GEMS™ Mobile ECG app,
    • Now available for download from the Google Play store
  • CardioComm Solutions’ Heartcheck(TM) CardiBeat Handheld ECG Device Cleared by Health Canada for Direct-to-Consumer Sales Read More
    • Received approval from Health Canada for the over-the-counter sales and marketing of its existing GEMS™ Mobile smartphone app and for the HeartCheck™ CardiBeat, its newest handheld heart rhythm monitor.
    • Both devices were cleared by the Food and Drug Administration in early 2019.
  • CardioComm Solutions Files with Health Canada for Direct to Consumer Sales Approval of the Heartcheck(TM) Cardibeat Handheld ECG Device Read More
    • Filed with Health Canada for approval for the over-the-counter  sales and marketing of their GEMS™ Mobile smartphone app and their newest handheld, heart rhythm monitor, the HeartCheck™ CardiBeat.
    • Both were cleared by the Food and Drug Administration in early 2019 and are available for sale direct to consumers in the US.

Company Accolades

FULL DISCLOSURE: CardioComm Solutions Inc. is an advertising client of AGORA Internet Relations Corp.

Tags: , , , , ,

Comments are closed.